UK markets close in 2 hours 13 minutes
  • FTSE 100

    7,491.43
    +2.24 (+0.03%)
     
  • FTSE 250

    18,925.09
    -5.48 (-0.03%)
     
  • AIM

    832.53
    -2.00 (-0.24%)
     
  • GBP/EUR

    1.1603
    -0.0009 (-0.07%)
     
  • GBP/USD

    1.2212
    +0.0007 (+0.06%)
     
  • BTC-GBP

    13,800.33
    -62.50 (-0.45%)
     
  • CMC Crypto 200

    396.52
    -5.51 (-1.37%)
     
  • S&P 500

    3,933.92
    -7.34 (-0.19%)
     
  • DOW

    33,597.92
    +1.58 (+0.00%)
     
  • CRUDE OIL

    74.47
    +2.46 (+3.42%)
     
  • GOLD FUTURES

    1,802.70
    +4.70 (+0.26%)
     
  • NIKKEI 225

    27,574.43
    -111.97 (-0.40%)
     
  • HANG SENG

    19,450.23
    +635.41 (+3.38%)
     
  • DAX

    14,239.85
    -21.34 (-0.15%)
     
  • CAC 40

    6,654.01
    -6.58 (-0.10%)
     

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic A/S
Bavarian Nordic A/S

COPENHAGEN, Denmark, November 24, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Gerard van Odijk

2.

Reason for the notification

a)

Position/status

Chairman of the Board of Bavarian Nordic A/S

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument


Identification code

Shares


DK0015998017

b)

Nature of the transaction

Sale

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 

 

DKK 236.00

2,153

d)

Aggregated information

  • Aggregated volume

  • Price



2,153
DKK 508,108.00

e)

Date of the transaction

2022-11-23

f)

Place of the transaction

Nasdaq Copenhagen A/S, XCSE


1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Gerard van Odijk

2.

Reason for the notification

a)

Position/status

Chairman of the Board of Bavarian Nordic A/S

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument


Identification code

Shares


DK0015998017

b)

Nature of the transaction

Sale

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 

 

DKK 236.00

850

d)

Aggregated information

  • Aggregated volume

  • Price



850
DKK 200,600.00

e)

Date of the transaction

2022-11-24

f)

Place of the transaction

Nasdaq Copenhagen A/S, XCSE

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 42 / 2022

Attachment